Anxiety disorders affect nearly one in five adults in the United States each year, making them one of the most common mental health conditions1 . Despite their high prevalence, diagnosis currently relies mainly on symptom checklists, which can lead to misdiagnosis and delayed or ineffective treatment2 . Recent advances in research have focused on developing blood tests that can objectively measure anxiety levels, predict future risk, and guide personalized treatment strategies3 4.
Blood Test Development for Anxiety
Developing a blood test for anxiety disorders is a complex challenge due to the brain’s inaccessibility and the intricate neurobiology involved2 . Unlike cancer, where liquid biopsies detect tumor-derived nucleic acids in blood for diagnosis and monitoring5 , psychiatric disorders lack direct tissue access, complicating biomarker discovery2 . However, peripheral blood can carry signals reflecting central nervous system changes through neuroimmune interactions, making it a promising source for anxiety biomarkers2 .
Recent research has employed transcriptomic analysis of blood samples to identify gene expression patterns linked to anxiety states. Longitudinal studies tracking individuals with psychiatric disorders have revealed changes in blood gene expression between low and high anxiety states2 . These studies use within-subject designs to detect dynamic biomarker fluctuations corresponding to anxiety severity, enabling more precise tracking over time6 .
A notable advancement comes from researchers at Indiana University School of Medicine, who developed a blood test examining 19 RNA biomarkers that track and predict anxiety levels and risk3 4. This test is not intended to diagnose anxiety but to measure current anxiety severity, assess future risk, and guide treatment selection by matching patients to medications associated with specific biomarkers3 4. The test was validated across multiple independent cohorts, including patients with major psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, and PTSD, many of whom had comorbid anxiety6 .
“If we can know that earlier, then we can hopefully avoid this pain and suffering and treat them earlier with something that matches their profile.”
— Alexander Niculescu, MD, PhD, Indiana University School of Medicine4
Key biomarkers identified include genes involved in neurotransmission, neurotrophic signaling, and stress response, such as GAD1 (Glutamate Decarboxylase 1), NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3), ADRA2A (Adrenoceptor Alpha 2A), and SLC6A4 (Serotonin Transporter) 6. These biomarkers reflect biological pathways relevant to anxiety pathophysiology and offer targets for repurposed or novel therapies6 .
Other peripheral blood components under investigation include inflammatory cytokines (e.g., IL-6, TNF-α), serotonin levels, brain-derived neurotrophic factor (BDNF), and microRNAs regulating gene expression related to stress and anxiety7 8. Elevated inflammatory markers have been observed in patients with anxiety disorders and PTSD, linking systemic inflammation to anxiety symptoms8 . Additionally, altered cholesterol profiles and oxidative stress markers have been associated with anxiety severity and suicidal ideation8 9.
The integration of gene expression data with clinical assessments and machine learning approaches has improved the predictive accuracy of anxiety risk and severity2 1011. Such multi-analyte blood tests could become valuable tools for early detection and personalized management of anxiety disorders.
Accurate Anxiety Testing Improves Treatment
“The current approach is to talk to people about how they feel to see if they could be on medications, but some medications can be addictive and create more problems.”
— Alexander Niculescu, MD, PhD, Indiana University School of Medicine4
Accurate and objective testing for anxiety disorders can significantly enhance treatment outcomes and reduce the prolonged trial-and-error approach often seen in clinical practice1 . Currently, diagnosis depends on subjective symptom reports and clinical interviews based on DSM-5-TR criteria, which may not capture the underlying biological causes or predict treatment response2 1.
💡 Did You Know? The blood test examines 19 biomarkers that could track and predict anxiety but is not designed to diagnose anxiety itself3 .
Blood biomarker tests can complement these assessments by providing objective evidence of anxiety severity and risk, helping clinicians tailor treatments more effectively2 . For example, the Indiana University blood test can identify which medications or nutraceuticals are most likely to benefit a patient based on their biomarker profile, potentially reducing reliance on addictive or ineffective drugs4 12.
Such tests also facilitate monitoring of anxiety over time, allowing for early intervention in high-risk individuals and adjustment of therapies as needed4 13. This approach supports preventative mental health care and may reduce the incidence of severe anxiety episodes and hospitalizations12 .
The complexity of anxiety disorders, involving multiple biological systems such as the hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system, and immune system, necessitates sophisticated tools for assessment and management8 . Biomarkers like cortisol, inflammatory cytokines, and neurotransmitter-related molecules provide insights into these systems’ involvement and can serve as indicators of disease state and treatment efficacy8 .
Machine learning models integrating blood biochemistry and psychosocial factors have shown promise in predicting anxiety disorder onset and resilience, highlighting the importance of combining biological and clinical data for optimal care11 .
Benefits of Accurate Anxiety Biomarker Testing:
- Objective measurement of anxiety severity and risk beyond self-reporting2 3
- Improved matching of patients to effective, non-addictive treatments4 12
- Early identification of individuals at risk for developing severe anxiety4 13
- Enhanced monitoring of treatment response and disease progression4
- Reduction of misdiagnosis and underdiagnosis, leading to better clinical outcomes2 1
